الفهرس 
Introduction and Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
- The immunochemical technique, enzyme-linked immunosorbent assay (ELISA), will be used to identify and quantify GPC3 concentrations in serum samples of patients with pancreatic, stomach and esophageal cancers. Furthermore, the relation between serum GPC3 status and clinicopathological data of patients such as age and sex and with other tumor markers as α-fetoprotein (AFP) were to be analyzed. Also, some biochemical parameters as Bilirubin and liver enzymes were assessed. Moreover, Anti-HCV and HBsAg were determined.
- No significant difference was seen in GPC3 level between male and female pancreatic cancer patients (P= 0.9582). Furthermore, the level of serum GPC3 in pancreatic cancer patients with age less than 55 years was nearly similar to that of patients with age more than 55 years meaning that serum GPC3 levels are not sex or age-related. On the other hand, there was a highly significant difference between the mean serum GPC3 value in both male and female pancreatic cancer patients from one side and both stomach and esophageal ones from the other side.
- No significant changes could be observed in the levels of GPC3 between pancreatic cancer patients with normal and abnormal liver enzymes (as AST and ALT) indicating that high level of serum GPC3 is not related to high liver enzymes or liver injury.
- High serum AFP concentrations were seen only in 13 out of 40 pancreatic cancer patients with a sensitivity of 32.5% compared to 87.5% for GPC3. This means that, the estimation of serum GPC3 might be preferred as a sensitive tumor marker for pancreatic cancer patients detected with a sensitivity of 87.5% more than AFP. Also the sensitivities of AFP for stomach and esophageal cancer patients were lower than that of GPC3 for the same patients (37.5% vs 75% for stomach and 25% vs 62.5% for esophageal patients).
- So, GPC3 was over expressed in pancreatic cancer patients with subsequent release and accumulation in the blood circulation. This accumulation enables the use of ELISA. It is also concluded that GPC3 can be used as a tumor marker for GIT tumors especially pancreatic cancer since its sensitivity was supreme to the well-known tumor marker AFP.